(Q28252209)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Julio Licinio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

J Kirchheiner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

K Nickchen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

M Bauer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

I Roots

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

J Brockmöller

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 May 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

442-473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

publication type of scholarly work

26 December 2019

review article

1 reference

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Biotransformation of Post-Clozapine Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Summary of information on human CYP enzymes: human P450 metabolism data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizoph

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Metabolism of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Chirality and drugs used in psychiatry: nice to know or need to know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Enantiomeric antidepressant drugs should be considered on individual merit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Non‐linear fluvoxamine disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Bupropion plasma levels and CYP2D6 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The role of cytochrome P450 2D6 in the metabolism of moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Venlafaxine serum levels and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Substantial rise in sparteine metabolic ratio during haloperidol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Clinical pharmacokinetics of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Antidepressive response to sleep deprivation in unipolar depression is not associated with dopamine D3 receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

SSRIs antidepressant activity is influenced by G beta 3 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Action of Atypical Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Genetic variation of the 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Synthesis of serotonin by a second tryptophan hydroxylase isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine receptor polymorphisms and drug response in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphisms in dopamine receptors: what do they tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

A polymorphism of the norepinephrine transporter gene in bipolar disorder and schizophrenia: lack of association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

A functional polymorphism in the monoamine oxidase A gene promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Psychotropic drugs, cardiac arrhythmia, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Genes for schizophrenia? Recent findings and their pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D4 receptor subtypes and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Pharmacogenetics of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Genetic variation of 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Dopamine D3 receptor variant and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

Response and Remission Rates in Different Subpopulations With Major Depressive Disorder Administered Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The Multifactorial Presentation of Depression in Acute Care

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

PCR-based genotyping for duplicated and deleted CYP2D6 genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The relationship between paroxetine and the sparteine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes*

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The CYP2D6 Genotype and Plasma Concentrations of Mianserin Enantiomers in Relation to Therapeutic Response to Mianserin in Depressed Japanese Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Influence of Cyp2D6 Genetic Polymorphism on Ratios of Steady-state Serum Concentration to Dose of the Neuroleptic Zuclopenthixol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Serotonin transporter gene polymorphism and antidepressant response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association analysis of a polymorphism in the G-protein stimulatory alpha subunit in patients with major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Increased serotonin-2 binding sites in frontal cortex of suicide victims

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Lack of Association Between Neuroleptic Malignant Syndrome and Polymorphisms in the 5-HT1A and 5-HT2A Receptor Genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Evidence for an Association between the Dopamine D3 Receptor Gene DRD3 and Schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Interaction of the ACE D allele and the GNB3 825T allele in myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Association between the methylenetetrahydrofolate reductase 677C-->T missense mutation and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Clozapine-induced hypersalivation and the alpha 2 adrenoceptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001494

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001494

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15037866%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017